TMED7-TICAM2

Across TCGA pan-cancer cohorts, TMED7-TICAM2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMED7-TICAM2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TMED7-TICAM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMED7-TICAM2 expression acts as an unfavorable survival marker.

OV, BLCA, and COAD are the cancer types where TMED7-TICAM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.278	0.843	<.001	36	view →
BLCA	OS	Median	III,IV	0.018	0.684	<.001	24	view →
COAD	DFS	Median	All	0.160	0.689	.017	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMED7-TICAM2–OV (OS)

Open the OV breakdown →